Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.
Ona Therapeutics's oversubscribed $86.6M Series B in June 2026 is European biotech at its most fundable: differentiated, validated science aimed at a hard clinical problem.
The problem this startup is attacking
Treatment-resistant cancers evade existing therapies. Ona develops first-in-class antibody-drug conjugates (ADCs) — targeted payloads designed to kill cancer cells that current drugs can't reach.
Why this is a live problem now
- ADCs are one of oncology's hottest modalities.
- Treatment resistance is a major unmet need.
- The reopening exit market improves European biotech funding appetite.
Competitive map
- Global ADC developers and big-pharma oncology pipelines.
- Other European clinical-stage biotechs.
Market signal (the number to remember)
- Oversubscribed $86.6M Series B — strong demand for a Barcelona biotech signals investor appetite for validated, differentiated oncology science.
Practical takeaway (operator + investor)
Ona shows European biotech can raise robustly on first-in-class science and clear clinical rationale. Founders should lead with mechanism and preclinical/clinical data; investors should keep European life sciences in the mix.
Sources
- Startuprise (Ona Therapeutics $86.6M Series B): https://startuprise.co.uk/top-funding-wrap-of-the-week-01-june-05-june-2026/
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
